98%
921
2 minutes
20
Prescription stimulant non-medical use (NMU) is a national predicament. While the risks of prescription stimulant NMU have been considered, less is known about non-oral use. To focus on this gap, a sample of adults with non-oral prescription stimulant NMU within the last 5-years was recruited. The purpose of the present study was to characterize the pathways and substance transitions associated with prescription stimulant NMU and non-oral prescription stimulant NMU in this unique sample of adults. Adults ( = 225) reporting non-oral prescription stimulant NMU within the last 5 years were recruited to complete an online survey by banner ads placed on the Reddit website between February and September 2019. After completion of the survey, a second study consisting of an in-depth telephone interview was conducted with 23 participants: interviews took place between July and September 2019. Data reported here include substance, route of administration and class transitions, as well as qualitative data from the interviews. Approximately 1 in 5 began their substance use trajectory with prescription stimulants (19.1%). Other than marijuana, most exposures to illicit substances occurred after both initial prescription stimulant NMU and initial non-oral prescription stimulant NMU. The most frequently reported route of administration transition was from oral use to snorting ( = 158, 70.2%), however, other route of administration transitions included oral use to injection drug use ( = 14, 6%). In-depth interviews elaborated upon these transitions and indicated that prescription stimulant NMU was consequential to substance use pathways. Oral prescription stimulant NMU was a precursor to non-oral prescription stimulant NMU. Non-oral prescription stimulant NMU was a precursor to illicit substance use, suggesting that prescription stimulant NMU impacts substance use pathways and revealing opportunities for intervention.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883730 | PMC |
http://dx.doi.org/10.3389/fpsyt.2020.631792 | DOI Listing |
J Epidemiol Community Health
September 2025
Nepean Medical School, The University of Sydney, Kingswood, New South Wales, Australia
Background: Children and young adults with attention-deficit/hyperactivity disorder (ADHD) may be at increased risk of criminal offending. This study examines the risk of first-time and repeat offending among individuals with ADHD and potential effect of stimulant medication.
Methods: A population-based, data linkage cohort study of individuals born in New South Wales, Australia between 1990 and 2005 and followed until May 2016.
J Arthroplasty
September 2025
Cleveland Clinic Foundation, Department of Orthopaedic Surgery, Cleveland, OH, USA 44195. Electronic address:
Introduction: The NarxCare Overdose Risk Score (ORS) is a measure of prescription drug use with scores ranging from 0 to 999, and higher scores suggest worse prescription drug use patterns, including opioids, sedatives, and stimulants. We aimed to evaluate the association of preoperative NarxCare ORS with clinically meaningful improvements in patient-reported outcome measures (PROMs) and satisfaction at one year.
Methods: Patients undergoing primary total knee arthroplasty (TKA) at an academic healthcare system (November 2018 to December 2022) were included.
Int J Clin Pharm
September 2025
School of Public Health, Western Gateway Building, University College Cork, Cork, Ireland.
Introduction: Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition, which initially presents in childhood. While prescribing trends for treating ADHD have been previously examined in Ireland's paediatric population, off-label prescribing of ADHD medication has yet to be studied.
Aim: We aimed to describe ADHD medication prescribing and off-label prescribing of ADHD medication in Ireland.
JAMA Netw Open
August 2025
Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: Early identification and treatment of attention-deficit/hyperactivity disorder (ADHD) symptoms in preschool-age children is important for mitigating social, emotional, and academic problems. Clinical practice guidelines recommend first-line behavior intervention before considering medication treatment for children aged 4 to 5 years.
Objective: To assess variation in rates of ADHD identification and rates and timing of medication initiation in children aged 3 to 5 years in primary care settings across 8 US pediatric health systems and to identify patient factors associated with the time from diagnosis to prescription.